Clinical Trials Directory

Trials / Completed

CompletedNCT02723968

Cystic Fibrosis Related Diabetes Screening.

Sensitivity and Specificity of Different Methods for Cystic Fibrosis-related Diabetes Screening.

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
29 (actual)
Sponsor
Hospices Civils de Lyon · Academic / Other
Sex
All
Age
10 Years – 18 Years
Healthy volunteers
Not accepted

Summary

Cystic fibrosis-related diabetes is a late cystic fibrosis (CF) associated comorbidity whose prevalence is increasing sharply lifelong. Guidelines for glucose metabolism (GM) monitoring relies on oral glucose tolerance test . However, this test is neither sensitive nor specific. The aim of this study is to compare sensitivity and specificity of different methods for GM monitoring in children and adolescents with CF. Continuous GM system (CGMS) will be used as the reference method. Results will be compared to those of oral glucose tolerance test (OGTT), intravenous glucose tolerance test (IGTT), homeostasis model assessment index of insulin resistance (HOMA-%IR) , homeostasis model assessment index of beta-cell function (HOMA-%B) and HbA1C dosage (glycated haemoglobin A1C). Patients will be classified into three groups according to CGMS: normal glucose tolerance, impaired glucose tolerance and diabetes mellitus.

Conditions

Interventions

TypeNameDescription
OTHERglucose solution at a dose of 1.75 g/kg (up to a maximum of 75 g) for the OGTT and glucose solution at a dose of 0.5 g/kg (up to a maximum of 35 g) was injected in 2.5-3 min for the IGTTAt the first visit at day 1an OGTT will be performed then the CGMS is implanted. Capillary glycaemia will be taken four times a day to set up the CGMS. A second visit is scheduled at day 4, where the intravenous glucose tolerance test is performed as well as the HbA1C level.
PROCEDUREHGPIV diagnosis test
PROCEDUREHOMAR-IR diagnosis test

Timeline

Start date
2009-09-01
Primary completion
2009-09-01
Completion
2012-04-01
First posted
2016-03-31
Last updated
2019-05-28

Source: ClinicalTrials.gov record NCT02723968. Inclusion in this directory is not an endorsement.